mcas and tirzepatide for diabetes: on track to SURPASS current therapy Therapeutic arsenal in MCAS. Development

The MHRA advises that insulin doses should not be reduced rapidly when initiating a GLP-1 receptor agonist, as this may increase the risk of diabetic ketoacidosis (DKA)

Keep tightly closed in a dry place, out of the reach of children, away from direct sunlight

Keep semaglutide in your personal bag, not checked luggage, where extreme cargo hold temperatures can compromise stability

So next time you think of glowing skin, think beyond the surface

Understanding GLP-1 Weight Loss Medications GLP-1 receptor agonists are a class of medications originally developed to treat type 2 diabetes, but they also induce substantial weight loss